BiondVax Pharma (BVXV) Reports Clinical Trial Agreement with NIH for U.S. Phase 2 Trial of Universal Flu Vaccine
Tweet Send to a Friend
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
